JP2023509441A - トファシチニブおよびフィンゴリモドを含む局所組成物 - Google Patents
トファシチニブおよびフィンゴリモドを含む局所組成物 Download PDFInfo
- Publication number
- JP2023509441A JP2023509441A JP2022540904A JP2022540904A JP2023509441A JP 2023509441 A JP2023509441 A JP 2023509441A JP 2022540904 A JP2022540904 A JP 2022540904A JP 2022540904 A JP2022540904 A JP 2022540904A JP 2023509441 A JP2023509441 A JP 2023509441A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight
- tofacitinib
- topical composition
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962955847P | 2019-12-31 | 2019-12-31 | |
| US62/955,847 | 2019-12-31 | ||
| US202063066717P | 2020-08-17 | 2020-08-17 | |
| US63/066,717 | 2020-08-17 | ||
| US202063086442P | 2020-10-01 | 2020-10-01 | |
| US202063086275P | 2020-10-01 | 2020-10-01 | |
| US63/086,275 | 2020-10-01 | ||
| US63/086,442 | 2020-10-01 | ||
| PCT/US2020/067612 WO2021138525A1 (en) | 2019-12-31 | 2020-12-31 | Topical composition comprising tofacitinib and fingolimod |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023509441A true JP2023509441A (ja) | 2023-03-08 |
| JP2023509441A5 JP2023509441A5 (cg-RX-API-DMAC7.html) | 2024-01-17 |
Family
ID=74285586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540904A Pending JP2023509441A (ja) | 2019-12-31 | 2020-12-31 | トファシチニブおよびフィンゴリモドを含む局所組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230037905A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4084776A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023509441A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020417290A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022012917A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163530A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294239A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202135825A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021138525A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010302350B2 (en) | 2009-10-02 | 2015-06-18 | Journey Medical Corporation | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US12661407B2 (en) | 2010-04-08 | 2026-06-23 | Journey Medical Corporation | Compositions, gels and foams with rheology modulators and uses thereof |
| JP7324210B2 (ja) * | 2018-01-31 | 2023-08-09 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッド | トファシチニブを含む局所製剤 |
| CN116437921A (zh) * | 2020-09-28 | 2023-07-14 | 株式会社Lg化学 | 鞘氨醇-1-磷酸酯受体激动剂的用途 |
| CN120168480A (zh) * | 2025-04-17 | 2025-06-20 | 四川省医学科学院·四川省人民医院 | 托法替尼在制备治疗干性年龄相关性黄斑变性的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874794A (en) | 1989-04-28 | 1989-10-17 | Lidak Biopharmaceuticals | Inflammatory disease treatment |
| US9474720B2 (en) | 2013-11-04 | 2016-10-25 | BioPharmX, Inc. | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers |
-
2020
- 2020-12-31 AU AU2020417290A patent/AU2020417290A1/en not_active Abandoned
- 2020-12-31 US US17/758,175 patent/US20230037905A1/en not_active Abandoned
- 2020-12-31 TW TW109147197A patent/TW202135825A/zh unknown
- 2020-12-31 WO PCT/US2020/067612 patent/WO2021138525A1/en not_active Ceased
- 2020-12-31 BR BR112022012917A patent/BR112022012917A2/pt not_active Application Discontinuation
- 2020-12-31 JP JP2022540904A patent/JP2023509441A/ja active Pending
- 2020-12-31 EP EP20845858.8A patent/EP4084776A1/en not_active Withdrawn
- 2020-12-31 CA CA3163530A patent/CA3163530A1/en active Pending
- 2020-12-31 IL IL294239A patent/IL294239A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3163530A1 (en) | 2021-07-08 |
| BR112022012917A2 (pt) | 2022-09-06 |
| EP4084776A1 (en) | 2022-11-09 |
| WO2021138525A1 (en) | 2021-07-08 |
| IL294239A (en) | 2022-08-01 |
| TW202135825A (zh) | 2021-10-01 |
| AU2020417290A1 (en) | 2022-05-26 |
| US20230037905A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7664358B2 (ja) | 水混和性の薬学的に許容可能な溶媒の水性ブレンド中のロフルミラストの医薬組成物 | |
| TWI240635B (en) | Active vitamin D3 emulsion lotion | |
| AU2010302350B2 (en) | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses | |
| JP7847143B2 (ja) | 皮膚疾患の治療のためのビタミンd類似体を有するjak阻害剤 | |
| US20230037905A1 (en) | Topical composition comprising tofacitinib and fingolimod | |
| US20200022912A1 (en) | Non Surface Active Agent Non Polymeric Agent Hydro-Alcoholic Foamable Compositions, Breakable Foams And Their Uses | |
| US20180235984A1 (en) | Tetracycline management of egfr inhibitor associated dermatoses | |
| US20240325393A1 (en) | Tofacitinib-containing anhydrous elastomer-based gel formulations | |
| EP3439632B1 (en) | Topical composition comprising tacrolimus | |
| KR20090084898A (ko) | 비타민 d 유도체를 포함하는 연고 조성물 | |
| JP2020505469A (ja) | 治療用アプレミラスト局所組成物 | |
| JP2022525221A (ja) | 洗い流し組成物および活性剤を送達するためのそれらの使用 | |
| AU2010335655B2 (en) | Calcipotriol monohydrate nanocrystals | |
| JP2022501314A (ja) | 局所用組成物 | |
| US20250339409A1 (en) | Uses of pan bet inhibitors | |
| AU2022399851A1 (en) | Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases | |
| CN115554243A (zh) | 一种治疗玫瑰痤疮的米诺环素泡沫剂 | |
| CN117157080A (zh) | 用于治疗皮肤病的含维生素d类似物的jak抑制剂 | |
| US20250073251A1 (en) | Compositions and methods and uses thereof | |
| WO2024220589A2 (en) | Uses of pan bet inhibitors cross-reference to related applications | |
| US20230320984A1 (en) | Tofacitinib-containing anhydrous elastomer-based gel formulations | |
| JP4060347B2 (ja) | 22−オキサ−1α,25−ジヒドロキシビタミンD3を含有する水中油型乳剤性ローション剤 | |
| WO2007086582A1 (ja) | 22-オキサ-1α,25-ジヒドロキシビタミンD3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法 | |
| JP4965884B2 (ja) | 吉草酸酢酸プレドニゾロンを含有するo/w型乳化製剤 | |
| JP5507600B2 (ja) | 吉草酸酢酸プレドニゾロンを含有するo/w型乳化製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231228 |